Revenue: As of FY2026 Q2, the actual value is USD 173.91 M, beating the estimate of USD 169.51 M.

EPS: As of FY2026 Q2, the actual value is USD -0.43, missing the estimate of USD -0.2.

EBIT: As of FY2026 Q2, the actual value is USD -21.45 M.

The provided reference, a Form 8-K filing from Tarsus Pharmaceuticals, Inc. dated August 6, 2026, indicates the company issued a press release detailing its results of operations for the three and six months ended June 30, 2026. However, the actual content of this press release, which would contain specific financial and operational metrics, as well as any outlook or guidance, is not included within the provided reference material. Consequently, no specific financial metrics, operational metrics, or outlook/guidance can be extracted directly from the given text .